Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC

Treatment options are expanding quickly in early non-small cell lung cancer. Listen as Heather Wakelee, MD, division chief of Medical Oncology at Stanford University and president of the  International Association for the Study of Lung Cancer, describes how she’s using new agents and incorporating trial findings into practice. She and host Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer, explore the growing roles for neo- and adjuvant therapy and how to select patients for each therapeutic approach.